Successful use of stapokibart as a biological therapy for allergic fungal rhinosinusitis: a case report
This pioneering case demonstrates that stapokibart, a novel anti-IL-4Rα antibody, is a promising and effective treatment for refractory AFRS, showing a rapid onset of action and sustained control of type 2 inflammation.
Authors
- Liuqing Zhou
- Cai Hua
- Ya-Qi Cao
- Xue-Jie Luo
- Jian-Jun Chen
- Sha-Zhou Li
- Tao Zhou
Institutions
- Center for Clinical Research (United States) (US)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Frontiers in Allergy
- Published
- 2026-01-14
- DOI
- https://doi.org/10.3389/falgy.2025.1746033
- Primary Topic
- Sinusitis and nasal conditions
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Hubei Province